Qiagen and Servier have recently announced a collaboration to create a new test for Acute Myeloid Leukemia (AML) drug. The test will be used to identify patients who are likely to respond to a specific type of AML drug called midostaurin. This new test will be based on the use of Qiagen’s proprietary technology, which is designed to detect genetic biomarkers in the blood of patients with AML.
The test will be used to identify patients who are likely to respond to midostaurin, an AML drug developed by Servier. Midostaurin is currently approved for use in the United States and Europe, and is used to treat adults with newly diagnosed AML. The new test will allow doctors to identify which patients are most likely to benefit from midostaurin treatment.
Qiagen’s proprietary technology is based on a process called next-generation sequencing (NGS). This process involves sequencing the DNA of a patient’s tumor cells to identify genetic mutations that may be associated with a particular type of cancer. By identifying these mutations, doctors can determine which patients are most likely to respond to a particular drug.
The new test developed by Qiagen and Servier will use NGS to identify genetic mutations in the blood of patients with AML. This will allow doctors to identify which patients are most likely to benefit from midostaurin treatment. The test is expected to be available in Europe and the United States later this year.
The new test is an important development in the treatment of AML. By identifying which patients are most likely to respond to midostaurin, doctors can provide more effective treatment for their patients. This could lead to improved outcomes for those suffering from this form of cancer.
Qiagen and Servier’s collaboration is an example of how two companies can work together to create innovative solutions for medical problems. By combining their expertise and resources, they have been able to develop a test that could potentially improve the lives of many people suffering from AML.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- Platoblockchain. Web3 Metaverse Intelligence. Knowledge Amplified. Access Here.
- Source: Plato Data Intelligence: PlatoAiStream
